With just a quick, one-second scan, users can see real-time glucose readings, as well as identify glucose trends with a directional arrow and review eight hours of glucose history.
In the U.S., the FreeStyle Libre system (10 day) is approved for replacement 2 of blood glucose monitoring (BGM) for adults with diabetes. The FreeStyle Libre system, which first launched in Europe in 2014, with a 14-day wear time, was the first to eliminate the need for fingersticks 10, and is designed to be an easier-to-use 2, streamlined 3 and more affordable system 4 compared with other available CGMs on the market. "With the new FreeStyle Libre 14 day system, people with diabetes will now have extended access to their glucose data with a high degree of accuracy, which will improve their experience and help empower them to better manage their condition." "At Abbott, we are continuously pushing for new innovations that minimize the daily burden of managing diabetes," said Jared Watkin, senior vice president, Diabetes Care, Abbott. This approval makes Abbott's revolutionary continuous glucose monitor (CGM) the longest lasting self-applied personal glucose sensor available on the market. Food and Drug Administration (FDA) has approved the FreeStyle ® Libre 14 day Flash Glucose Monitoring system, which allows people with diabetes to wear the sensor up to 14 days with high accuracy. ABBOTT PARK, Ill., J/ PRNewswire/ - Abbott (NYSE: ABT) today announced that the U.S.
0 kommentar(er)
